Journal
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
Volume 31, Issue 2, Pages 391-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.iac.2011.02.012
Keywords
Intralymphatic allergen-specific immunotherapy; Epicutaneous allergen-specific immunotherapy; Vaccination route; Intralymphatic vaccination; Epicutaneous vaccination
Categories
Funding
- Swiss National Science Foundation (SNF)
- University of Zurich, Medanz Medical GmbH (Starnberg, Germany)
- Allergy Innovations (Munich, Germany)
- Mann Kind Corporations (Valencia, CA, USA)
- ImVisioN GmbH (Hannover, Germany)
Ask authors/readers for more resources
For the past century, subcutaneous allergen-specific immunotherapy has been the state-of-the-art treatment for IgE-mediated allergic disease. Current research on allergen-specific immunotherapy is focused on enhancing its efficacy, safety, and patient convenience with the goal of offering a broadly accepted treatment option. There is a growing interest in intralymphatic allergen-specific immunotherapy because it is a highly efficacious and safe treatment route that requires only 3 injections. Concurrently, epicutaneous allergen-specific immunotherapy is attracting increasing attention because of its capacity to offer a safe, needle-free, and potentially self-administrable treatment option for IgE-mediated allergic diseases. In this article, we discuss the principles and immunologic rationale of these unconventional routes of allergen-specific immunotherapy while highlighting their developmental process and clinical relevance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available